Novartis cuts outlook, faces U.S. Tasigna delay
472694
Novartis AG lowered its full-year results outlook as generic competition pressured sales of a key blood-pressure drug, and said U.S. regulators had delayed the approval process for an important cancer treatment.
272184
NEW YORK -- Pfizer Inc. will probably slash staff and accelerate merger and licensing deals, as the pressure on it to improve its financial performance intensifies after the weekend's announcement that the company has ended development of a key drug.
148195
The supply of low-cost generic versions of cancer and AIDS treatments for the developing world could be blocked if Novartis wins a legal challenge to Indiaâs patent law.
67567
Chiron (CHIR:Nasdaq - news - research) said Thursday that it had found some problems with the production of its Fluvirin influenza virus vaccine, which will cause a delay in the product&#39;s reaching the market until early October.
164503
Shares of Chiron Corp. CHIR.O fell 7  percent before the market open on Friday, a day after the  biopharmaceutical company said it is delaying shipment of its  flu vaccine, Fluvirin, because lots containing 4 million  vaccines do not meet product sterility standards.
535410
Shares of Possis Medical Inc. fell more than 28 percent before the market open Tuesday, on news that it had cut its revenue outlook due to the poor performance of its AngioJet blood clot device in clinical trials.
458999
Merck & Co.  said on Friday it  would delay seeking approval for a combination pill designed to  lower "bad" cholesterol, increase "good" cholesterol and avoid  a common side effect of one of the ingredients.
52712
Shares in AstraZeneca fell 109p to Â£25.10 yesterday on news that its potential blockbuster drug offering stroke prevention, Exanta, might face delays in getting American approval.
32469
Accredo Health Inc. (ACDO.O: Quote, Profile, Research) , which provides pharmacy and treatment services for patients with chronic illnesses, on Monday slashed its profit forecast due to
471279
The Thursday night rejection of Proctor &amp; Gamble&#39;s (PG:NYSE - news - research) female testosterone sex-drive patch Intrinsa by a Food and Drug Administration advisory panel will almost certainly delay efforts by BioSante to develop its own product, a
143021
Swiss pharmaceutical maker Novartis AG reported a 45 percent drop in fourth-quarter net profit on Thursday, citing restructuring costs and a weak performance in the U.S. market.
550684
Sanofi-Aventis SA cut its 2006 earnings forecast Friday, warning that generic drug maker Apotex Corp. may have flooded the U.S. market with cheaper copies of the French company's blockbuster blood-thinning pill, Plavix.
466550
Credit Suisse First Boston lowered 2005 earnings estimates for Pfizer (nyse: PFE - news - people ) after the generic version of Neurontin was launched earlier than expected.
371920
By Linda Loyd, The Philadelphia Inquirer  Dec. 7--Cephalon Inc. shares fell today after the company said U.S. regulators will likely delay final approval of its drug Nuvigil for excessive sleepiness as the agency investigates a case of a serious rash with a related medicine.
268630
Shares of Accredo Health Inc. ACDO.O  sank in trade before the opening bell after the provider of  pharmacy and treatment services for patients with chronic  illnesses slashed its fiscal 2005 profit forecast.
140996
A day late and possibly several millions of dollars short. That's the scenario facing one drug manufacturer unless it can get a helping hand from Congress.
257211
Swiss pharmaceutical giant Novartis AG said Tuesday it is temporarily withdrawing an application for European Union approval of its painkiller Prexige, but added that it will present new data this week to prove the safety and effectiveness of the drug.